Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Bettina Kotter"'
Autor:
Niels Werchau, Bettina Kotter, Elvira Criado-Moronati, Andre Gosselink, Nicole Cordes, Dominik Lock, Simon Lennartz, Carolin Kolbe, Nora Winter, Karin Teppert, Fabian Engert, Brian Webster, Joerg Mittelstaet, Daniel Schaefer, Peter Mallmann, Michael R. Mallmann, Dominik Ratiu, Mario Assenmacher, Thomas Schaser, Michael von Bergwelt-Baildon, Pierre Abramowski, Andrew D. Kaiser
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
Solid tumors consist of malignant and nonmalignant cells that together create the local tumor microenvironment (TME). Additionally, the TME is characterized by the expression of numerous soluble factors such as TGF-β. TGF-β plays an important role
Externí odkaz:
https://doaj.org/article/c33c72814d7043f49b55860008ccb5cf
Autor:
Nicole Cordes, Carolin Kolbe, Dominik Lock, Tatjana Holzer, Deborah Althoff, Daniel Schäfer, Franziska Blaeschke, Bettina Kotter, Sandra Karitzky, Claudia Rossig, Toni Cathomen, Tobias Feuchtinger, Iris Bürger, Mario Assenmacher, Thomas Schaser, Andrew D. Kaiser
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 21, Iss , Pp 42-53 (2021)
Recently, a rare type of relapse was reported upon treating a B cell acute lymphoblastic leukemia (B-ALL) patient with anti-CD19 chimeric antigen receptor (CAR)-T cells caused by unintentional transduction of residual malignant B cells (CAR-B cells).
Externí odkaz:
https://doaj.org/article/c35a2ae8e0aa4f12be416e571f892b51
Autor:
Nicole Cordes, Nora Winter, Carolin Kolbe, Bettina Kotter, Joerg Mittelstaet, Mario Assenmacher, Toni Cathomen, Andrew Kaiser, Thomas Schaser
Publikováno v:
Viruses, Vol 14, Iss 10, p 2157 (2022)
Selective gene delivery to a cell type of interest utilizing targeted lentiviral vectors (LVs) is an efficient and safe strategy for cell and gene therapy applications, including chimeric antigen receptor (CAR)-T cell therapy. LVs pseudotyped with me
Externí odkaz:
https://doaj.org/article/eee4d9380673423ba066e75f1c54c09c
Autor:
Christian M. Seitz, Joerg Mittelstaet, Daniel Atar, Jana Hau, Selina Reiter, Clara Illi, Verena Kieble, Fabian Engert, Britta Drees, Giulia Bender, Ann-Christin Krahl, Philipp Knopf, Sarah Schroeder, Nikolas Paulsen, Alexander Rokhvarguer, Sophia Scheuermann, Elena Rapp, Anna-Sophia Mast, Armin Rabsteyn, Sabine Schleicher, Stefan Grote, Karin Schilbach, Manfred Kneilling, Bernd Pichler, Dominik Lock, Bettina Kotter, Sandra Dapa, Stefan Miltenyi, Andrew Kaiser, Peter Lang, Rupert Handgretinger, Patrick Schlegel
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Chimeric antigen receptor (CAR)-T therapy holds great promise to sustainably improve cancer treatment. However, currently, a broad applicability of CAR-T cell therapies is hampered by limited CAR-T cell versatility and tractability and the lack of ex
Externí odkaz:
https://doaj.org/article/856cb793555a4203b03dee394ed2e07f
Autor:
Bettina Kotter, Fabian Engert, Winfried Krueger, Andre Roy, Wael Al Rawashdeh, Nicole Cordes, Britta Drees, Brian Webster, Niels Werchau, Dominik Lock, Sandra Dapa, Dina Schneider, Stephan Ludwig, Claudia Rossig, Mario Assenmacher, Joerg Mittelstaet, Andrew D. Kaiser
Publikováno v:
Cancers, Vol 13, Iss 19, p 4741 (2021)
Chimeric antigen receptor (CAR) T cell therapy has emerged as an attractive strategy for cancer immunotherapy. Despite remarkable success for hematological malignancies, excessive activity and poor control of CAR T cells can result in severe adverse
Externí odkaz:
https://doaj.org/article/07057e4a21204bbf93f5df4b75d47c2f
Autor:
Andrew Kaiser, Daniel Schäfer, Iris Bürger, Franziska Blaeschke, Mario Assenmacher, Thomas Schaser, Claudia Rossig, Nicole Cordes, Toni Cathomen, Tobias Feuchtinger, Carolin Kolbe, Sandra Karitzky, Deborah Althoff, Tatjana Holzer, Dominik Lock, Bettina Kotter
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 21, Iss, Pp 42-53 (2021)
Molecular Therapy. Methods & Clinical Development
Molecular Therapy. Methods & Clinical Development
Recently, a rare type of relapse was reported upon treating a B cell acute lymphoblastic leukemia (B-ALL) patient with anti-CD19 chimeric antigen receptor (CAR)-T cells caused by unintentional transduction of residual malignant B cells (CAR-B cells).
Autor:
Stephan Ludwig, Brian Webster, Fabian Engert, Winfried Krueger, Andrew Kaiser, Andre Roy, Mario Assenmacher, Wa'el Al Rawashdeh, Dominik Lock, Dina Schneider, Nicole Cordes, Claudia Rossig, Joerg Mittelstaet, Britta Drees, Bettina Kotter, Niels Werchau, Sandra Dapa
Publikováno v:
Cancers
Volume 13
Issue 19
Cancers, Vol 13, Iss 4741, p 4741 (2021)
Volume 13
Issue 19
Cancers, Vol 13, Iss 4741, p 4741 (2021)
Simple Summary Chimeric antigen receptor (CAR) T cell therapy can be associated with substantial side effects primarily due to intense immune activation following treatment, or target antigen recognition on off-tumor tissue. Consequently, temporal an
Publikováno v:
E-Poster Presentations.
Background Adoptive transfer of chimeric antigen receptor (CAR)-modified T cells has emerged as a promising treatment modality for a broad range of cancers highlighted by the approval of Kymriah™ and Yescarta™ for the treatment of B cell malignan